Valganciclovir as CMV reactivation prophylaxis in patients receiving alemtuzumab for marrow failure syndromes

Annals of Hematology

Volumn 88, Issue 12, 2009, Pages 1261-1262

  Risitano, Antonio M ^a   Serio, Bianca ^a   Selleri, Carmine ^a   Rotoli, Bruno ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; COTRIMOXAZOLE; CYCLOSPORIN A; VALGANCICLOVIR;

APLASTIC ANEMIA; BACTERIAL INFECTION; BONE MARROW DEPRESSION; CANCER RELAPSE; CD4 LYMPHOCYTE COUNT; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; LETTER; LOW DRUG DOSE; MYCOSIS; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PURE RED CELL ANEMIA; PURE WHITE CELL APLASIA; SIDE EFFECT; VIRUS REACTIVATION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; BONE MARROW DISEASES; CLINICAL TRIALS, PHASE II AS TOPIC; GANCICLOVIR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; RECURRENCE; SYNDROME;

EID: 70350292707     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-009-0749-z     Document Type: Letter

References (10)

1. Elter T, Vehreschild JJ, Gribben J, Cornely OA, Engert A, Hallek M (2008) Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab. Ann Hematol 88:121-132
2. Rosenfeld S, Follmann D, Nunez O, Young NS (2003) Antithymocyte globulin and cyclosporine for severe aplastic anemia: Association between hematologic response and long-term outcome. JAMA 289:1130-1135. doi: 10.1001/jama.289.9.1130
3. Risitano AM, Selleri C, Serio B, Marando L, Camera A, Catalano L, Scalia G, Del Vecchio L, Rotoli B (2007) Subcutaneous alemtuzumab is safe and effective for treatment of global or single-lineage immune-mediated marrow failure: A pilot study. Blood 110:1692a
4. Scheinberg P, Fischer SH, Li L, Nunez O, Wu CO, Sloand EM, Cohen JI, Young NS, John Barrett A (2007) Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia. Blood 109:3219-3224. doi: 10.1182/ blood-2006-09-045625
5. Nguyen DD, Cao TM, Dugan K, Starcher SA, Fechter RL, Coutre SE (2002) Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Clin Lymphoma 3:105-110. doi: 10.3816/CLM.2002.n.016
6. Laurenti L, Piccioni P, Cattani P, Cingolani A, Efremov D, Chiusolo P, Tarnani M, Fadda G, Sica S, Leone G (2004) Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: Incidence and treatment with oral ganciclovir. Haematologica 89:1248-1252
7. Chakrabarti S, Mackinnon S, Chopra R, Kottaridis PD, Peggs K, O'Gorman P, Chakraverty R, Marshall T, Osman H, Mahendra P, Craddock C, Waldmann H, Hale G, Fegan CD, Yong K, Goldstone AH, Linch DC, Milligan DW (2002) High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: Potential role of Campath-1H in delaying immune reconstitution. Blood 99:4357-4363. doi: 10.1182/blood.V99.12.4357
8. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD (1993) Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 118:173-178
9. Ayala E, Greene J, Sandin R, Perkins J, Field T, Tate C, Fields KK, Goldstein S (2006) Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 37:851-856. doi: 10.1038/ sj.bmt.1705341
10. O'Brien S, Ravandi F, Riehl T, Wierda W, Huang X, Tarrand J, O'Neal B, Kantarjian H, Keating M (2008) Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood 111:1816-1819. doi: 10.1182/blood-2007-03-080010